56044-12-3

Usage

Uses

Used in Pharmaceutical Industry:
2,4-DIOXO-1,2,3,4-TETRAHYDRO-QUINAZOLINE-6-SULFONYL CHLORIDE is used as a reactant for the preparation of prostaglandin agonists. Prostaglandins are a group of lipid compounds that have various physiological effects, including the regulation of blood flow, inflammation, and pain. They are essential in the treatment of various conditions, such as bone disorders.
In the pharmaceutical industry, 2,4-DIOXO-1,2,3,4-TETRAHYDRO-QUINAZOLINE-6-SULFONYL CHLORIDE plays a crucial role in the synthesis of prostaglandin agonists, which are used to treat bone disorders. These agonists help in the regulation of bone metabolism, promoting bone formation and preventing bone loss, thus providing relief and improving the quality of life for patients suffering from such conditions.

Upstream product

• 86-96-4 1,2,3,4-tetrahydro-quinazoline-2,4-dione 

Downstream Products

• 1332356-03-2 N-((2S,3R)-1-(2-(2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl-sulfonyl)hydrazinyl)-3-hydroxy-1-oxobutan-2-yl)benzenesulfonamide 
• 1214468-35-5 2,4-dioxo-N-[4-(pyridin-3-yloxy)phenyl]-1,2,3,4-tetrahydroquinazoline-6-sulfonamide 

Relevant academic research and scientific papers

Quinazolines 1. Synthesis and chemical reactions of 6-chlorosulfonyl- quinazoline-2,4-diones

Treatment of quinazoline-2,4-dione and its symmetrical 1,3-dialkyl derivatives with chlorosulfonic acid gave the corresponding 6- chlorosulfonylquinazoline-2,4-diones. Reaction of the compounds obtained with nucleophilic agents (water, ammonia, aliphatic and cyclic amines) gave the corresponding free 2,4-dioxoquinazoline-6-sulfonic acids, 6- sulfamidoquinazoline-2,4-diones, and 2,4-dioxoquinazoline-6-sulfonic acid amides.

Synthesis and characterization of the first inhibitor of: N -acylphosphatidylethanolamine phospholipase D (NAPE-PLD)

N-Acylphosphatidylethanolamine phospholipase D (NAPE-PLD) is a membrane-associated zinc enzyme that catalyzes the hydrolysis of N-acylphosphatidylethanolamines (NAPEs) into fatty acid ethanolamides (FAEs). Here, we describe the identification of the first small-molecule NAPE-PLD inhibitor, the quinazoline sulfonamide derivative 2,4-dioxo-N-[4-(4-pyridyl)phenyl]-1H-quinazoline-6-sulfonamide, ARN19874.

2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.